The treatment of moderate to severe Alzheimer’s disease is reviewed with regard to mechanisms of action, pharmacokinetics, metabolism, safety/tolerability, and efficacy in reducing cognitive, behavioral/psychiatric, functional and global symptoms. The cholinesterase inhibitors donepezil, rivastigmine and galantamine and the N-methyl-d-aspartate receptor channel blocker memantine are moderately ...

Treatments for the symptomatic relief of Alzheimer's disease are available but despite advances in our ability to treat persons with various forms of dementia, more effective treatments are needed. The cholinesterase inhibitors donepezil, rivastigmine, and galantamine have demonstrated efficacy in improving cognition and global status and to a lesser extent, behavioral abnormalities relative to...

A rapid, sensitive, simple, and cost-effective spectrofluorimetric method was developed for the estimation of rivastigmine in bulk and pharmaceutical formulations. The relative fluorescence intensity of rivastigmine was measured in triple distilled water at an excitation wavelength of 220 nm and an emission wavelength of 289 nm. Linearity range was found to be 100 to 4000 ng/ml. The method was ...

Abstract Background Gait impairments are common in patients with Alzheimer’s disease. Cholinesterase inhibitors used to treat the symptoms of disease, but they have not been shown reduce severity disease-related gait disorders. Methods This was a prospective, single-arm, open-label, non-randomized study. The aim present study determine effect acetylcholinesterase inhibitor rivastigmine on 21 ne...

BACKGROUND/AIMS The present study evaluated the differences in treatment outcomes and brain perfusion changes among 3 types of acetylcholinesterase inhibitors (AchEIs, i.e. donepezil, rivastigmine, and galantamine). METHODS This was a prospective, longitudinal, randomized, open-label, 3-arm (donepezil, rivastigmine, or galantamine), parallel-group, 12-month clinical trial carried out in 55 pa...

OBJECTIVES To study the efficacy of cholinesterase inhibitors in the treatment of dementia in patients with Parkinson's disease (PD). METHODS We treated twenty-eight demented patients with PD openly for 26 weeks with rivastigmine (mean daily dose 7.2 +/- 3.3 mg/day). Baseline scores were compared with those at weeks 12, 26 and after 8 weeks of washout. RESULTS Twenty patients completed 26 w...

Cholinesterase inhibitors such as donepezil, galantamine and rivastigmine can slow the progression of Alzheimer’s disease and provide symptomatic relief but require daily administration (donepezil) or twice daily administration (galantamine and rivastigmine). These medications, of course, only have efficacy if actually taken on a regular basis. A clinical vignette is described here of a patient...

A new series of 27 diethyl 2-(phenylcarbamoyl)phenyl phosphorothioates (thiophosphates) was synthesized, characterized by NMR, IR and CHN analyses and evaluated against Mycobacterium tuberculosis H37Rv, Mycobacterium avium and two strains of Mycobacterium kansasii. The best activity against M. tuberculosis was found for O-{4-bromo-2-[(3,4-dichlorophenyl)carbamoyl]phenyl} O,O-diethyl phosphoroth...

We presented the patient with relative younger Alzheimer’s disease (AD) whose clinical symptoms and cognitive functions were responsive not to donepezil but to rivastigmine. Age of initial visit our memory clinic of this patient was relatively younger. It is considered that in relative older patient both AD pathology and aging cause cognitive dysfunctions. However, in relative younger patient n...